SYED, ISMAIL;
DE CELIS, MARIA FERNANDEZ RUBIN;
MOHAN, JAMES F.;
MORAES-VIERIA, PEDRO M.;
VIJAYAKUMAR, ARCHANA;
NELSON, ANDREW T.;
SIEGEL, DIONICIO;
SAGHATELIAN, ALAN;
MATHIS, DIANE;
KAHN, BARBARA
361-OR: ER Stress Attenuation Is Involved in PAHSA-Induced Reduction of T1D in Nonobese Diabetic (NOD) Mice
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
361-OR: ER Stress Attenuation Is Involved in PAHSA-Induced Reduction of T1D in Nonobese Diabetic (NOD) Mice
Contributor:
SYED, ISMAIL;
DE CELIS, MARIA FERNANDEZ RUBIN;
MOHAN, JAMES F.;
MORAES-VIERIA, PEDRO M.;
VIJAYAKUMAR, ARCHANA;
NELSON, ANDREW T.;
SIEGEL, DIONICIO;
SAGHATELIAN, ALAN;
MATHIS, DIANE;
KAHN, BARBARA
Description:
<jats:p>Palmitic Acid esters of Hydroxy Stearic Acids (PAHSAs) are endogenous lipids with antidiabetic and anti-inflammatory effects. We found that PAHSAs protect against T1D by attenuating autoimmune responses and by direct effects on islets. We aimed to determine the mechanisms by which PAHSAs directly promote β-cell survival. Daily oral gavage of PAHSAs in NOD mice starting at 4 or 13 weeks of age delays T1D onset and reduces T1D incidence from 82-90% of mice with vehicle to 35-40% of mice receiving PAHSAs. PAHSA treatment reduces leukocyte infiltration into islets by 50% and reduces T cell activation. PAHSA-treated mice had greater β-cell area relative to total islet area (vehicle 60±7 vs. PAHSA 77±1). PAHSAs enhance β-cell proliferation in NOD mice 5 fold vs. vehicle. PAHSA-treated NOD mice pancreata have lower ER stress markers, CHOP and XBP-1 (vehicle 68±12 vs. PAHSA 42±3), and higher insulin (vehicle 12±2 vs. PAHSA 17±1) immunostaining intensities per β-cell area. PAHSAs attenuate thapsigargin-induced PARP cleavage by 55% in human islets, and JNK1/2 phosphorylation by 40% in MIN6 cells. Also, PAHSAs attenuate apoptotic and necrotic β-cell death under cytokine stress and increase β-cell viability by 34% and proliferation by 31% (p&lt;0.002). Since GLP-1 receptor (GLP-1R) antagonism causes β-cell death and G-protein coupled receptor GPR40 plays a vital role in β-cell function, we assessed if PAHSA beneficial effects on β-cell survival involve these pathways. In vitro, GLP-1R antagonism lowered PAHSA protective effects on β-cell viability by 53% and proliferation by 44% (p&lt;0.005) under cytokine stress but GPR40 antagonism had no effect.</jats:p>
<jats:p>Conclusion: In addition to attenuating immune responses, PAHSAs delay the onset and reduce T1D incidence in NOD mice through direct effects. PAHSAs directly reduce cytokine-induced β-cell death and increase cell proliferation in autoimmune diabetes through mechanisms involving ER stress reduction. This appears to be mediated in part by GLP-1R and not by GPR40.</jats:p>
<jats:sec>
<jats:title>Disclosure</jats:title>
<jats:p>I. Syed: None. M. Fernandez Rubin de Celis: None. J.F. Mohan: None. P.M. Moraes-Vieria: None. A. Vijayakumar: None. A.T. Nelson: None. D. Siegel: None. A. Saghatelian: None. D. Mathis: None. B. Kahn: Advisory Panel; Self; Alterna Therapeutics, Inc., American Diabetes Association, Harrington Discovery Institute, Janssen Research & Development. Consultant; Self; Ironwood Pharmaceuticals, Inc. Research Support; Self; National Institute of Diabetes and Digestive and Kidney Diseases.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Funding</jats:title>
<jats:p>National Institutes of Health (R01DK43051, P30DK57521 to B.K.), (R01DK106210 to B.K., A.S.), (K01DK118041 to I.S.); JPB Foundation (to B.K., D.M.); Deutsche Forschungsgemeinschaft (to M.F.R.)</jats:p>
</jats:sec>